Pharming Group: Building a sustainable rare disease business, preparing for approval/launch of leniolisib for APDS. Revenues >$200M (TTM) from Ruconest (marketed) for the treatment of acute hereditary angioedema (HAE) attacks including breakthrough attacks. Leniolisib, a targeted PI3Kδ inhibitor initially being developed for PI3K delta syndrome (APDS), is on track to be the first approved disease-modifying treatment for APDS, a rare genetic immunodeficiency. Regulatory approvals expected from the US FDA in Q1 2023 and EU EMA in H1 2023 under priority review/ accelerated assessment, with commercial launch expected in the US H1 and EU H2 2023. Ruconest cash flow funds leniolisib and broader pipeline development. Dual listed on Nasdaq.